Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis  by Feofanov, A. et al.
Biophysical Journal Volume 73 December 1997 3317-3327
Localization and Molecular Interactions of Mitoxantrone within Living
K562 Cells as Probed by Confocal Spectral Imaging Analysis
Alexei Feofanov,* Serguei Sharonov,# Irina Kudelina,* Fabrice Fleury,# and Igor Nabiev#
*Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow, Russia, and
#Laboratoire de Spectroscopie Biomol6culaire, UFR de Pharmacie, Universite de Reims Champagne-Ardenne,
51096 Reims Cedex, France
ABSTRACT Studying mechanisms of drug antitumor action is complicated by the lack of noninvasive methods enabling
direct monitoring of the state and interactions of the drugs within intact viable cells. Here we present a confocal spectral
imaging (CSI) technique as a method of overcoming this problem. We applied this method to the examination of localization
and interactions of mitoxantrone (1, 4-dihydroxy-5, 8-bis-{{[2-(2-hydroxyethyl)-amino]ethyl}amino}-9,10-anthracenedione
dihydrochloride), a potent antitumor drug, in living K562 cells. A two-dimensional set of fluorescence spectra of mitoxantrone
(MITOX) recorded with micron resolution within a drug-treated cell was analyzed to reveal formation of drug-target complexes
and to create the maps of their intracellular distribution. The analysis was based on detailed in vitro modeling of drug-target
(DNA, RNA, DNA topoisomerase 11) interactions and environmental effects affecting drug fluorescence. MITOX exposed to
aqueous intracellular environment, MITOX bound to hydrophobic cellular structures, complexes of MITOX with nucleic acids,
as well as the naphtoquinoxaline metabolite of MITOX were simultaneously detected and mapped in K562 cells. These states
and complexes are known to be immediately related to the antitumor action of the drug. The results obtained present a basis
for the subsequent quantitative analysis of concentration and time-dependent accumulation of free and bound MITOX within
different compartments of living cancer cells.
INTRODUCTION
Preclinical screening and investigation of new drugs for
chemotherapy is directly related to the identification of
critical biochemical targets and analysis of cellular factors
responsible for cytotoxic action of the drugs. The combined
application of conventional biochemical and cytological
methods with noninvasive quantitative techniques such as
flow cytometry and laser scanning confocal fluorescence
microscopy (LSCFM) may be considered the most effective
approach to determining the cytotoxic potential and phar-
macological features of antitumor drugs.
Flow cytometry and LSCFM are widely used to examine
the uptake and localization of fluorescent compounds or
labeled fluorescence probes in intact, viable cells (Pawley,
1990; McLean Grogan and Collins, 1990). These techniques
analyze an integral fluorescence signal selected by the
broad-band filter. When spectral parameters of a fluores-
cence probe are known to be unchanged, or (the opposite)
they change considerably and specifically because of intra-
cellular interactions, the flow cytometry and LSCFM enable
precise quantitative analysis. By the use of a set of different
filters, the interactions and/or environmental characteristics
of specific fluorescence probes with well-separated spectral
characteristics may be simultaneously recognized in cells.
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More generally, when interactions of fluorophores are
manifested only by subtle spectral changes, their identifica-
tion is more ambiguous. Yet particular intracellular interac-
tions of such fluorophores like, for example, anticancer
drugs, may be of great interest. Indeed, when the signals
from drug-target complexes, a free drug, and the cell intrin-
sic fluorescence overlap, they cannot be separated and iden-
tified with the restricted set of broad-band filters.
Recently a new approach based on confocal spectral
imaging (CSI) analysis has been developed (Sharonov et al.,
1994a,b; Feofanov et al., 1995). Combining a laser confocal
scanning microscope with a spectrograph and a charge
coupled device (CCD) detection system, the CSI technique
allows the 2D set of spectra to be recorded with submicron
3D spatial resolution from an intact living cell treated with
a fluorescent drug. To create the spectral images describing
subcellular localization and interactions of a drug, the de-
composition procedure should be applied to the set of the
recorded spectra. According to this procedure, each original
spectrum is decomposed into a sum of the reference spectra
with appropriate coefficients. The reference spectra origi-
nating from in vitro modeling are attributed to different
states and specific interactions of the fluorophore. Such an
approach also enables enhancement/quenching of fluores-
cence of the drug localized in different states to be taken
into account. This advantage of the CSI technique is ex-
tremely important for correct analysis, but it is not a prop-
erty of either flow cytometry or LSCFM if the analyzed
signals overlap.
As compared to the "similarity mapping procedure" re-
alized recently (Malik et al., 1996), the spectral decompo-
sition technique is more general and convenient. The "sim-
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ilarity mapping procedure" calculates the degree of
difference between the shape of the experimental spectrum
at the current point of the sample and the shape of a single
reference spectrum and creates 2D maps of similarity. The
real intensity of the experimental spectrum, which charac-
terizes the concentration of a fluorophore, is omitted in this
approach. Moreover, when the coefficient of similarity is
not unity, the contribution of the reference spectrum is not
clear. In a general case, an experimental spectrum is a
superposition of several states and their relative contribu-
tions are quite important, but cannot be identified by using
the "similarity mapping procedure." Nevertheless, this ap-
proach is well suited to assigning a measured signal to one
of several possible reference signals (Liyanage et al., 1996).
In our preliminary report (Sharonov et al., 1994a), the
CSI technique was demonstrated to be useful in the study
of the antitumor agent mitoxantrone (1,4-dihydroxy-5,8-
bis-{I [2-(2-hydroxyethyl)-amino]ethyl}amino 1-9, 10-anthra-
cenedione dihydrochloride; NSC301739). Mitoxantrone
(Novatrone), a synthetic anthraquinone drug (Fig. 1), shows
considerable activity against a wide variety of animal tumor
models (Fujimoto and Ogawa, 1982; Johnson et al., 1979),
as well as in the clinical treatment of acute nonlymphocytic
leukemia, advanced breast cancer, and non-Hodgkin's lym-
phomas (Arlin et al., 1990; Ehninger et al., 1990; Faulds et
al., 1991). The exact mechanisms responsible for the anti-
tumor action of mitoxantrone (MITOX) have yet not been
elucidated. There may be a number of mechanisms involv-
ing the formation of MITOX-DNA complexes (Smith et al.,
1990; Kapuscinski et al., 1986), complexes of MITOX with
cytoskeleton proteins (Roberts et al., 1989; Ho et al., 1991),
and/or accumulation of cytotoxic metabolites (Mewes et al.,
1993). Here we apply the CSI technique to direct monitor-
ing of localization and interactions of MITOX within living
cells. We are starting from a detailed study of environmental
factors and molecular interactions affecting the parameters
of MITOX fluorescence. The considerable sensitivity of
MITOX fluorescence to interactions and environmental fac-
tors revealed in this work demonstrates that in vitro mod-
eling of drug-target interactions should be regarded as an
important primary step toward the situ study of drug uptake,
distribution, and interactions. It predetermines the correct
use of the CSI technique, as well as flow cytometry and
LSCFM for drug analysis in living cells.
Based on the results of in vitro modeling, several states
and interactions of MITOX within K562 cells were identi-
fied by the CSI technique: MITOX in an aqueous environ-
ment, MITOX bound to hydrophobic cellular structures, and
MITOX bound to nucleic acids. The naphtoquinoxaline
metabolite of MITOX was also detected in drug-treated
cells. The basis set of the reference spectra, which is well
suited to describing the state and interactions of MITOX,
was obtained, and it was proved to be adequate in deter-
mining the accumulation and localization of MITOX in
K562 cells.
MATERIALS AND METHODS
Enzymes, nucleic acids, and reagents
Calf thymus DNA, calf liver RNA (type IV), horseradish peroxidase
(crude), and Triton X-100 (t-octylphenoxypolyethoxyethanol) were pur-
chased from Sigma (St. Louis, MO) and used as received. Calf thymus
DNA topoisomerase 11 (0.18 x 106 units/mg) was a gift of Rhone-Poulenc
Rorer, S.A. (France). One unit of topoisomerase II (topo II) was defined as
described earlier (Nabiev et al., 1994). Mitoxantrone was a gift of Lederle
Laboratories (Rungis). A stock solution (0.1 mM) of MITOX was prepared
in phosphate-buffered saline (PBS) for both cell treatments and in vitro
experiments. Concentration of MITOX in the aqueous buffer solutions was
measured by absorption at the isosbestic point at Ai = 682 nm, using the
extinction coefficient EAj = 8.36 X 103 M-1 cm-' (Kapuscinski et al.,
1981). It should be mentioned that MITOX adsorbs thoroughly (2 x 10-'1
mollcm2) at the walls of a plastic culture dish. Accordingly, appropriate
correction was made for the drug concentration when working with a
10-6 M concentration of the drug.
All other chemicals were of analytical-reagent grade, and all solvents







K562 is a human erythroleukemic cell line, established from a patient with
chronic myelogeneous leukemia in blast transformation. Cells were grown
exponentially at 3-7 X 105 cells/ml in RPMI-1640 (Gibco, Grand Island,
NY) containing 10% fetal calf serum (Seromed) and 2 mM L-glutamine
(Sigma). After the incubation with MITOX (10 ,uM drug for 1 h or 2 AM
drug for 1 h), the cells were rinsed two times with PBS, resuspended with
fresh PBS, and placed under a microscope for measurement.
NQX
FIGURE 1 Structure of MITOX and its naphthoquinoxaline metabolite
(NQX).
Preparation of complexes and reaction mixtures
for in vitro modeling experiments
The concentration of DNA (RNA) in the solution was 1 13 ,tM (97 ,mM) in
base pairs. Drug-DNA and drug-RNA complexes were prepared by mixing
the components in PBS buffer at the initial MITOX/DNA and MITOX/
RNA molar ratios of 1/100 bp and 1/80 bp, respectively. The titration
procedure was performed by incrementally adding MITOX from the stock
solution to reach the final drug/DNA and drug/RNA molar ratios of 1/10 bp
and 1/14 bp, respectively. The concentration of DNA was determined by
absorption at 260 nm (e = 6600 M- 1 (bp) cm-l).
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The ternary cleavable complexes of MITOX with topo II and DNA were
prepared in the 50-,l final reaction volume of PBS containing 4 ,uM
MITOX, 50 units of topo II, and 240 ,uM DNA. The components were
mixed at 4°C and incubated at 37°C for 20 min, and then a drop of reaction
mixture was placed under the microscope.
Oxidation of MITOX by horseradish peroxidase was initiated by mixing
a 2-mi solution of PBS containing 10 ,tM MITOX and 80 ,uM hydrogen
peroxide with 2 ,ul of the enzyme (1 mg/ml). Reaction was self-terminated
by reaching the equilibrium state after -20 min. The further oxidation of
MITOX did not occur during the next 3-4 h, as was detected by absorp-
tion. Formation of the naphthoquinoxaline (NQX) derivative of MITOX
was confirmed by the appearance of the characteristic absorption spectrum
of NQX with maxima at 584 and 628 nm (Reszka et al., 1986) instead of
the spectrum of MITOX. Numerical decomposition (Gigli et al., 1988) of
the fluorescence spectrum measured from the reaction mixture led us to the
conclusion that the -4/1 molar ratio was achieved between NQX and
MITOX at the equilibrium state.
To probe the disturbance of MITOX spectral parameters in the presence
of topo II, 50 units of the enzyme was added to the 50-j,l final reaction
volume of PBS containing 4 ,uM MITOX.
Detergent-containing solutions of MITOX (10 ,uM) were prepared at
the critical micelle concentration of Triton X-100 (0.24 mM) in the PBS
buffer. Solutions of MITOX (10 ,uM) were also prepared at 4 mM and 50
mM concentrations of Triton X-100.
Solutions of MITOX in methanol, ethanol, and propanol as well as a
solution of NQX in dioxane were prepared at the drug concentration of
10 ,uM.
Spectral measurements
Fluorescence spectra were measured with a Hitachi MPF-3 fluorimeter
(Japan). Circular dichroism (CD) spectra were recorded with a Jasco-SOOC
dichrograph (Japan), and a Cary-209 spectrophotometer (Varian, Sunny-
vale, CA) was used for absorption measurements. Microfluorescence anal-
ysis of solutions and CSI measurements of cells were performed with a
modular Raman/fluorescence XY-500 spectrometer (DILOR, France)
equipped with a microscope (Olympus BH2, Japan), confocal entrance
chamber, and a system of galvanometer-controlled mirror scanners (Feo-
fanov et al., 1995). Microfluorescence measurements were carried out with
a IOOX phase contrast objective (Olympus UVFL100PL). The spectral
resolution was 0.15 nm. The spatial resolution was -1 ,um (lateral reso-
lution) and -3 p.m (axial resolution). Spectral images were accumulated
and treated as described previously (Feofanov et al., 1995; Sharonov et al.,
1994a,b).
Briefly, the focused laser beam scanned a specimen along a line. The
fluorescence signal emitted by the specimen was decomposed after con-
focal filtration by the spectrometer into a spectrum and detected by CCD
camera. The spectra from different points of the specimen scanning line
were projected onto different rows of CCD pixels. The whole 2D set of
spectra was recorded by the line-by-line scanning method. To create the 2D
spectral images presented in this paper, a spectrum decomposition proce-
dure or a procedure based on the integration of the signal over the selected
spectral region was applied.
The spectrum decomposition procedure was based on the deconvolution
of each experimental spectrum into a sum of the reference spectra with
appropriate coefficients. The least-squares linear regression algorithm was
employed to calculate decomposition coefficients. 2D maps of the decom-
position coefficients (hereafter referred to as spectral images) describe the
relative distribution along the specimen of each component; the spectrum
of each component was introduced as a reference. The reference spectra
were taken from in vitro modeling measurements. The validity of the
performed procedure was proved by calculating a map of errors for each
decomposition.
The 50 x 50 or 40 x 40 pixel spectral images were recorded with the
514.5-nm excitation wavelength of an Ar+ laser (model 2020-03; Spectra
Physics) at 0.1 mW. The recording time of a spectral image did not exceed
lular structure was observed under the experimental conditions used. By
repeating image measurements, we could ascertain that probing of the
drug-target interactions with a laser beam affected neither the initial pattern
of the drug distribution and interactions, nor the intact cellular structure. It
was found that the influence of laser radiation on a cell appeared only after
several (usually 5-7) repetitions of image recording (20-28 min of
irradiation).
RESULTS
In vitro studies of MITOX interactions by
fluorescence, absorption, and CD techniques
Dimerization of MITOX in water solution
Increasing concentration leads to dimerization of MITOX
molecules (Kd = 3 X 104 M-1) in water solution (Kapus-
cinski and Darzynkiewicz, 1985). The dimers are detected
by measuring the ratio of intensities at the long- and short-
wavelength absorption maxima (RA) of MITOX (Table 1).
The RA ratio equal to 1.33-1.36 for monomeric MITOX is
reduced significantly because of dimer formation (Kapus-
cinski and Darzynkiewicz, 1985). The dimerization drasti-
cally changes the concentration of monomeric MITOX from
-95% at a total drug concentration (Ctot) of 1 ,uM to -34%
at CtOt = 0.1 mM. The dependence of the fluorescence
intensity on Ctot measured by microspectrofluorometry and
corrected for the effect of the inner filter reveals a saturation
(Fig. 2 a). On the other hand, the fluorescence intensity is
directly proportional to the concentration of monomeric
MITOX in solution (Fig. 2 a). The positions of the maxi-
mum (Amax = 685 nm) and the shape of the emission
spectrum corrected for reabsorption of the emitted light are
independent of dimer content in solution. Moreover, the
shape of the excitation spectrum is very similar to that of the
absorption spectrum of monomeric MITOX (Fig. 2 b).
These observations suggest that the dimers of MITOX do
not fluoresce, so that only the monomeric form of the drug
contributes to the fluorescence spectrum.
The drug aggregation depends on the pH of the solution
increasing sharply, producing a basic environment (Table
1). It is detected by a remarkable decrease in both fluores-
cence intensity and the RA coefficient, which occurs on
going from a neutral (pH 7.4) to a basic (pH 10) environ-
ment. The aggregation was found to be reversible, and
should be related to deprotonation of NH3+ groups of the
aminoalkylamino side chains at basic pH. A pH decrease
from 7.4 to 4.0 is followed by only a slight fluorescence
increase (Table 1). In a similar manner, a small increase in
the drug fluorescence may occur in acidic compartments of
the cell as well as in the microenvironment, where the local
pH is reduced. The position of the maximum and the shape
of the emission spectrum are not affected by pH.
Effect of solvent polarity and interactions with
hydrophobic micelles
The influence of environment polarity on the spectral prop-
4 min. Neither bleaching of intracellular MITOX nor disturbance of cel-
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TABLE I Spectral parameters of absorption and fluorescence spectra of mitoxantrone and its naphtoquinoxaline metabolite in
different environmental conditions, complexes, and mixtures
Absorption Fluorescence#
FWHM'
Solvent, conditions* Amaxl (nm) Amax2 (nm) RA§ Amax (nm) (nm) Irel
MITOX, 100% monomers,*" 610 661 1.34 685 58 1.0
PBS (pH 7.4)
MITOX, PBS (pH 10) 614 665 0.56 685 58 0.08
MITOX, PBS (pH 7.4) 610 661 0.87 685 58 0.7
MITOX, PBS (pH 4.5) 610 661 0.95 685 58 0.8
MITOX, MeOH 615 667 1.19 686 58 2.9**
MITOX, MeOH:CHCl3 1:1 618 671 1.20 690 56 2.9**
MITOX, EtOH 620 673 1.36 692 49 2
MITOX, propanol 623 675 1.34 694 46 2.1
MITOX, Triton X-100'q 610 661 1.18 685 54 2.1**
MITOX-DNA (1/17 bp) 628 680 1.34 700 50 0.65##
MITOX-RNA (1/14 bp) 626 678 1.34 688 61
MITOX-RNA (1/29 bp) 627 679 1.34 690 56
MITOX-DNA-topo II 700 50 0.6500
MITOX-topo II 685 58 l.0*0
NQX, PBS (pH 7.4) 587 631 0.75 6521§ 46§§
NQX, dioxane 588 636 1.2 652 36
*Concentrations of the components and experimental conditions are described in Materials and Methods.
#Intensities were corrected for the effect of inner filter. Excitation wavelength 514.5 nm.
*The ratio of absorbance at Amax2 to that at kmaxl.
1Full width of spectrum at the half of maximum.
'Relative intensity as compared with the intensity of equimolar aqueous solution of monomeric MITOX.
**Calculated using the data from (Kapuscinski and Darzynkiewicz, 1985).
'Corrected for the concentration of the monomeric MITOX in the solution studied.
§§Contribution of mitoxantrone signal was subtracted.
"1Concentration of Triton X-100 is equal to 0.24 mM.
the drug dissolved in different solvents. A moderate in-
crease in hydrophobicity (methanol < methanol:chloro-
form < ethanol < propanol) was found to correlate with a
progressing red-shift of the fluorescence emission and ab-
sorption maxima of the drug (Table 1). The red-shift of the
emission maximum is accompanied by a decrease in the
spectrum bandwidth (Table 1).
Because the shapes of the fluorescence excitation and
absorption spectra of the drug are similar, and the latter has
a RA ratio of - 1.34 (Table 1), MITOX could be concluded
to exist in a monomeric form in ethanol and propanol
solutions. Similar reasoning shows that MITOX is less
aggregated in methanol and methanol:chloroform solutions
compared to the aqueous solution. Therefore, increasing
environmental hydrophobicity induces dissociation of the
drug's dimers. In addition, an elevation of fluorescence
intensity by approximately twofold was detected for mono-
meric MITOX in ethanol and propanol solutions, as com-
pared to the aqueous buffer solution at 514.5-nm excitation.
The ability of MITOX to penetrate the hydrophobic re-
gions of vesicles and membranous structures was estimated
by mixing MITOX with detergent micelles. The fluores-
cence emission spectrum of the drug is not changed in
solutions containing Triton X-100 micelles, except for en-
hancement of intensity. Taking into account an increase in
the RA ratio to 1.18 (Table 1), dissociation of the dimers
caused by interaction ofMITOX with the detergent micelles
can be assumed. Because this interaction does not induce a
red-shift of the emission spectrum, there is no increase in
environmental hydrophobicity. Therefore, the binding of
MITOX occurs at the micelle surface without penetration of
the drug molecule into the hydrophobic region of the mi-
celle. Formation of hydrogen bonds between amino groups
of MITOX and hydroxyl groups of the detergent molecules
is the most probable mode of binding. As for the approxi-
mately twofold enhancement of fluorescence (Table 1), it
seems that interactions of the amino groups with the micelle
molecules eliminate the partial quenching of the fluores-
cence of chromophore moiety by the amino groups that
occurs for the free molecules. It is known (Burstein, 1976)
that external amino groups quench chromophore fluores-
cence in solution, whereas interactions of these groups
(deprotonation, intermolecular hydrogen binding, etc.)
eliminate quenching and enhance fluorescence.
The results suggest that MITOX weakly penetrates hy-
drophobic structures. Nevertheless, forced contacts with
hydrophobic groups or domains may be expected at the
cellular level. Some unprofitable (in terms of entropy) hy-
drophobic interactions seem to be possible if compensated
for by electrostatic interactions and/or hydrogen binding of
MITOX to polar or negatively charged groups of the sur-
rounding molecules. This conclusion is confirmed by a
red-shift of the fluorescence emission when MITOX was
mixed with Triton X-100 at an enormous concentration of
3320 Biophysical Journal
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FIGURE 2 (a) Dependencies of the fluorescence intensity on the total
concentration of MITOX (asterisks) and on the concentration of mono-
meric MITOX (+) in the PBS solution, pH 7.4. (b) Absorption (+) and
fluorescence excitation (*) spectra of 10 ,uM MITOX solution in PBS (pH
7.4) as well as simulated (according to the data of Kapuscinski and
Darzynkiewicz, 1985) absorption spectrum of monomeric MITOX (O) in
aqueous solution. The dependence of intensity on the total concentration of
MITOX was measured by microspectrofluorometry and corrected for the
effect of the inner filter. The concentration of monomeric MITOX was
calculated using the dimerization constant Kd = 3 x 104 M-Il (Kapuscinski
and Darzynkiewicz, 1985).
the detergent (50 mM, data not shown). In this case laminar
structures rather than uniform micelles were formed in the
aqueous solution. Multiple contacts of MITOX molecules
with the hydrophobic regions of detergent laminar struc-
tures should be realized and may be responsible for the
red-shift of the drug fluorescence.
Interactions with DNA and RNA
MITOX binds to double-stranded (ds) nucleic acids via
intercalation (Kapuscinski and Darzynkiewicz, 1985;
Reszka et al., 1989). Apart from intercalation, electrostatic
interactions are known to occur between DNA phosphate
groups and aminoalkylamino side chains of MITOX (Durr
et al., 1983; Kapuscinski and Darzynkiewicz, 1986). Anal-
ysis of CD spectra (not shown), which is based on the CD
spectra of different forms of DNA (Ivanov, 1973), reveals
that an increase in a drug/bp ratio from 1/100 to 1/5 is
accompanied by unwinding of the DNA helix. Finally,
precipitation of the drug-DNA complex occurs at drug/bp
ratios higher than 1/5.
The absorption spectrum of the drug-DNA complex is
red-shifted and less intense as compared to the spectrum of
free monomeric MITOX (Kapuscinski and Darzynkiewicz,
1985). Drug-DNA interaction causes a considerable red-
shift of the fluorescence maximum, changes in the shape
and bandwidth of the fluorescence spectrum (Table 1), as
well as a decrease in fluorescence intensity (-35%). Fluo-
rescence parameters of the drug-DNA complexes were
found to be independent for a drug/bp ratio in the range
from 1/100 to 1/5 (data not shown). It means that the
contribution of a free drug to the spectrum of the drug-DNA
complex is negligible at each drug/bp ratio used. This fact
can be explained as follows:
1. A 20-fold increase in the drug/bp ratio leads to only
1.67-fold growth of the relative concentration of the free
drug (from 8.4% to 14% of Ct.t), according to the binding
constant of K = 2.52 X I05 M-1 published elsewhere
(Kapuscinski and Darzynkiewicz, 1985).
2. Quenching of fluorescence of the free drug occurs
because of nonradiative energy transfer from the molecule
to the drug/DNA complex. The energy transfer is very
effective, because the emission spectrum of the free drug
(Amax = 685 nm) extensively overlaps the excitation spec-
trum of the drug-DNA complex (Amax, = 680 nm).
MITOX was also found to bind with RNA. On interaction
with RNA, the emission spectrum broadens and red-shifts
(Table 1) as a function of a drug/bp ratio. The spectrum
decomposition procedure indicates that the spectrum of the
MITOX-RNA complex can be considered as a superposi-
tion of the spectra of free MITOX and MITOX-DNA com-
plex. Analysis of CD spectra of the drug-RNA complexes
(not shown), which is based on the CD spectra of different
forms of RNA and DNA (Ivanov, 1973), reveals that 1) calf
liver RNA has the structure of a ds helix, and 2) unwinding
of RNA helix occurs as the drug/bp ratio increases.
These data allow a similar mode of drug interaction with
both ds RNA and ds DNA to be suggested. The strong
contribution of free MITOX to the spectrum of the drug-
RNA complex can be explained by weaker binding of the
drug to RNA versus DNA, stemming from the differences in
the structure of double-stranded helixes of these biopoly-
mers (Saenger, 1984).
Native RNA is recognized to form either a long ds helix
or a single-stranded globular structure, according to its
biological function. In the latter case, short double-stranded
fragments are developed under folding of the RNA single
chain into a globule (Saenger, 1984). Therefore, the inter-
calation binding mode, which is stabilized by electrostatic
interactions involving anionic groups of RNA and amino
Feofanov and Charonov 3321
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groups of the side chains of MITOX, can be expected for
either type of RNA.
Modeling the drug interactions with DNA topoisomerase I1
Formation of cleavable complexes between MITOX, topo
II, and DNA does not induce any new spectral changes, as
compared to the fluorescence emission spectrum of the
MITOX-DNA complex (Table 1). The fluorescence spec-
trum of the drug is not perturbed by the addition of topo II
to MITOX alone. It can be concluded that the chromophore
moiety of MITOX is unable to interact with topo II alone,
and intercalation of DNA should be considered as a first
step toward the formation of the cleavable complex. More-
over, interaction of the chromophore with DNA (namely, its
intercalation) is unaffected by binding of topo II to the
drug-DNA complex. It should be mentioned that the data
obtained agree with the generally accepted mechanism of
the cleavable complex formation in the presence of topo II
poisons (D'Agra and Liu, 1989). At the same time, the data
of fluorescence spectroscopy do not preclude the interac-
tions of the aminoalkylamino side chains of MITOX with
topo II alone or within the ternary cleavable complex,
because such interactions hardly affect the fluorescence of
the chromophore moiety.
Spectral features of the naphtoquinoxaline metabolite
of mitoxantrone
The absorption and fluorescence emission spectra of the
NQX metabolite are blue-shifted compared to those of
MITOX (Table 1). The fluorescence emission spectrum of
the NQX metabolite narrows in dioxane versus the aqueous
buffer, but no shift of the maximum occurs (Table 1). The
absorption spectrum of the NQX metabolite is slightly red-
shifted in dioxane. The RA value (Table 1) points to the
dissociation of NQX dimers in dioxane as compared to the
state of the NQX metabolite in aqueous buffer. The NQX
metabolite has both proton-accepting and proton-donating
sites (Fig. 1), and its H-bonding state is different in dioxane,
an acceptor solvent, as related to that in the aqueous buffer.
Hence hydrogen bonding of NQX to the proton-accepting
sites of dioxane molecules is responsible for the narrowing
of the fluorescence spectrum.
Microspectrofluorometry of K562 cells treated
with mitoxantrone
Intrinsic fluorescence of cells
The intensity of the cellular fluorescence was found to vary
within different cellular compartments (Fig. 3). The nucleus
does not fluoresce when excited at 514.5 nm, but intense
fluorescence was observed from within cytoplasmic com-
partments of the cells. The strongest intrinsic cellular fluo-
rescence was detected from cytoplasmic regions adjacent to
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FIGURE 3 (a) Conventional light-microscope image of the cell. (b)
Confocal spectral image of this cell created basing on the integral signal of
intrinsic cellular fluorescence excited at the 514.5 nm wavelength. (c)
Spectra of the intrinsic fluorescence of the cell (curves 1-3) recorded from
within different cytoplasmic compartments. The regions from which the
spectra were recorded (curves 1-3) are marked on the confocal spectral
image of the cell. Curve 4, Integral spectrum of the intrinsic fluorescence
of the cell constructed by averaging of the intrinsic fluorescence spectra
from different cellular compartments.
out to be the same in every fluorescent region of cytoplasm
(Fig. 3 c). The spectra are broad. They have two overlapped
maxima at 640 and 652 nm, as well as a shoulder at -700
nm (Fig. 3 c, curve 4). The shape of the intrinsic fluores-
cence spectra was found to persist in the drug-treated cells.
Analysis of the spectra recorded from
mitoxantrone-treated cells
The spectra recorded from different regions of MITOX-
treated cells were found to differ in intensity, shape, width,
and the position of the maximum (Fig. 4). Because these
distinctions were obviously related to intracellular interac-
tions of MITOX, their origin was identified by using the
results of in vitro experiments. The spectra of MITOX
disposed within nucleoli or perinucleolar regions of the
nucleus were found to coincide with the spectrum of the
MITOX-DNA complex with a small contribution of the
monomeric drug (Fig. 4 a). The spectra from within some
cytoplasmic compartments were well simulated by the spec-
trum of MITOX in propanol solution (Fig. 4 b). The spectra
characteristic of the monomeric MITOX in aqueous envi-
ronment were detected in other cytoplasmic compartments
(Fig. 4 d). A narrow maximum was observed at 652 nm in
the spectra recorded from within extranuclear compartments
(Fig. 4, c and d). As discussed below, the unique parameters
(position of maximum and width) of this band coincide with







Intracellular Localization and Interactions of Mitoxantrone
FIGURE 4 Several examples of the spectral analysis (decomposition procedure) of microfluorescence spectra (.) recorded from within the nucleus (A)
and different cytoplasmic compartments (B-D) of MITOX-treated cells. The decomposition of measured spectra into components was performed using the
set of in vitro measured model spectra, which describe (curve 1) nucleic acid-related complexes of MITOX, (curve 2) MITOX in a hydrophobic
environment, (curve 3) monomeric MITOX in polar environment, (curve 4) NQX metabolite bound to the ligands, as well as (curve 5) the intrinsic cellular
fluorescence signal. The validity of the decomposition procedure can be estimated by comparing the spectra (curve 6) simulated on the basis of components
1-5 with the experimental spectra (. ). Spectra 1-5 show the relative contribution of each component to the overall spectrum.
The intrinsic cellular fluorescence contributes fairly well to
the overall signal (Fig. 4, c and d), especially when a low
concentration of the drug is used for treatment. Typically,
the spectra appeared as a superposition of different signals
(Fig. 4 c), which were assigned by means of the decompo-
sition procedure.
The comprehensive analysis of the spectra recorded from
the MITOX-treated cells permitted us to define a set of the
reference spectra suitable for describing the state and inter-
actions of MITOX in the K562 cells. This set includes 1) the
spectrum of monomeric MITOX in an aqueous environ-
ment, 2) the spectrum of MITOX in propanol, 3) the spec-
trum of the MITOX-DNA complex, 4) the spectrum of the
NQX metabolite in dioxane, and 5) the spectrum of the
intrinsic cellular fluorescence.
Spectrum 2) may be considered to describe forced hy-
drophobic contacts and/or the nonpolar environment of
MITOX bound to hydrophobic cellular structures. Spectrum
3) allows simulation of the complexes between MITOX and
DNA, including ternary complexes between MITOX, DNA,
and topo II in cells. Moreover, intercalation of MITOX in
the ds fragments of RNA is readily modeled by this spec-
trum, as it follows from our in vitro experiments. Spectrum
4) is introduced to feature the distribution of the NQX
metabolite within the cells.
Spectral images were recorded from more than 30 cells
treated with both high (10 ,uM) and low (2 ,uM) concentra-
tions of MITOX. Every spectral pattern of MITOX in the
K-562 cells was examined and found to be well simulated,
based on the set of reference spectra. The average error of
the decomposition procedure was estimated to be 5-7%.
Spectral detection of NQX metabolite in K-562 cells
Microfluorescence spectra (Aexc = 514.5 nm) recorded
in the cytoplasmic region of the K562 cells treated with
MITOX have a narrow maximum at 652 nm (Fig. 4, c and
d. This spectral feature was obviously drug-related, because
it was absent from the spectra recorded from control cells
(Fig. 3 c), and its intensity correlated with a concentration-
dependent increase in the intracellular MITOX signal. At
the same time, this feature was not observed in modeling
environmental effects and interactions of MITOX with pos-
sible molecular targets in vitro. It was proposed that it
corresponds to one of MITOX metabolites. Among 11 me-
tabolites of MITOX found in HepG2 hepatoma cells, the
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only NQX metabolite has an absorption spectrum that blue-
shifted by 30 nm compared to the MITOX spectrum
(Mewes et al., 1993). Thereby, we predesignate the metab-
olite as a source of the peak at 652 nm. Absorption spectra
of all other metabolites were reported to be red-shifted
(Mewes et al., 1993). The NQX metabolite obtained in vitro
as a result of MITOX oxidation catalyzed by horseradish
peroxidase exhibits a fluorescence emission maximum at
652 nm (Table 1), thus coinciding with the maximum of the
band under consideration.
To detect selectively the signal corresponding to the 652
nm feature, the microfluoresence spectra of drug-treated
cells were recorded at the 488-nm excitation. A contribution
of MITOX itself decreased, and a narrow 652-nm band was
observed only in these spectra, yet it coincided (width,
shape, and position of maximum) with the spectrum of
NQX in dioxane. Taken together, these results permitted us
to assign the 652-nm band in the microfluorescence spectra
of the drug-treated cells to the NQX metabolite of MITOX.
The state of the NQX metabolite in the cellular environ-
ment is modeled by its spectrum in dioxane rather than in
the aqueous solution. Therefore, the NQX metabolite is
bound to the acceptor groups of cellular structures or mol-
ecules within the cytoplasmic region of the cells.
Confocal spectral images of mitoxantrone in K562 cells
The confocal spectral images were recorded from the equa-
torial optical sections of cells. The layer of 3-,um thickness
contributed to the collected signal. The 514.5-nm excitation
was used to record confocal spectral images, because the
NQX metabolite, monomeric MITOX in an aqueous intra-
cellular environment, MITOX bound to hydrophobic cellu-
lar structures, and complexes of MITOX with DNA may be
simultaneously detected and mapped at this excitation (Fig.
5). Spectral images based on the fluorescence signal inte-
grated over the selected spectral range (so-called band-pass
images) were also created for comparative purposes. They
are analogous to conventional LSCFM images, but in the
former case, the width and position of spectral range used as
a band-pass filter may be widely varied.
In accordance with the observations made previously by
the LSCFM technique for SV40 transformed human fibro-
blasts (Smith et al., 1992) the integral fluorescence signal of
MITOX was detected from within the cytoplasm, nuclear
membrane, and nucleoli of K562 cells (Fig. 5, b and c).
Nevertheless, both enhancement of fluorescence in nonpo-
lar environment and partial fluorescence quenching of MI-
TOX bound to DNA distort the drug disposition that ap-
pears in confocal spectral band-pass images (Fig. 5, b and c)
and LSCFM images (Smith et al., 1992). Moreover, the
intrinsic cellular fluorescence introduces a perceptible con-
tribution to the integral signal, especially when a low drug
concentration is used for cell treatment. Both a complicated
shape of the spectrum and overlapping with the spectra of
the drug make it impossible to account for the intrinsic
FIGURE 5 Confocal spectral images of the cell exposed to 10 ,mM
MITOX concentration for 1 h. (a) Conventional light-microscope image of
the cell. (b) Band-pass image (650 ± 5 nm). (c) Band-pass image (690 ±
5 nm). (d-h) Spectral images describing the distribution of monomeric
MITOX in the aqueous intracellular environment (d), nucleic acid related
complexes of MITOX (e), MITOX bound to the hydrophobic cellular
structures (f), NQX metabolite bound to the ligands (g), and the intrinsic
cellular fluorescence signal (h). The bar in a corresponds to 2 ,um.
cellular fluorescence contribution to the overall signal in
band-pass images.
By decomposing the intracellular spectra into reference
spectra of MITOX in different states and correcting for
enhancement and quenching of corresponding signals, the
real pattern of the drug disposition is revealed, and more-
over, the features of the drug interactions are clearly ob-
served (Fig. 5, d-g). Because the spectra heavily overlap,
these interactions cannot be identified in band-pass images,
regardless of the spectral region chosen to integrate signal.
Monomeric MITOX in an aqueous microenvironment,
MITOX bound to hydrophobic cellular structures, and the
NQX metabolite are distributed throughout the cytoplasm,
whereas the presence of the MITOX-nucleic acid com-
plexes in cytoplasm is quite negligible (Fig. 5, d, f, g). The
overall signal of the drug within the nucleus is undoubtedly
related to the drug-DNA complexes, with contributions
from the MITOX-DNA-topo II and MITOX-RNA com-
plexes (Fig. 5 e). Perinucleolar staining and increased ac-
cumulation of MITOX in nucleolar-like bodies are detected.
The patterns of subcellular distribution of monomeric
MITOX located in an aqueous environment and the NQX
metabolite have similar features: besides the drug being
uniformly distributed in the cytoplasm, compact regions of
drug accumulation are observed near the nucleus. The re-
gions of concentrated MITOX and the NQX metabolite
coincide with the sites of intense intrinsic cellular fluores-
i
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cence. General staining of hydrophobic cellular structures
and capture of the drug in small hydrophobic inclusions are
apparent in the cytoplasmic region of the cells for MITOX
(referred to as bound to hydrophobic cellular structures).
The distribution of the drug along the equatorial optical
section was compared to 3D distribution of the drug within
the cell. The 3D analysis was performed by measuring the
spectral images at different optical sections of the cell (at
different positions of the focal plane). Three series of con-
focal spectral images of the cell obtained at the equatorial
optical cross section, and at 3 ,um and 6 ,um above it, are
presented in Fig. 6. The 3D analysis reveals similar features
of the drug distribution and interactions as described above
for the equatorial cross sections.
DISCUSSION
Recently Smith et al. (1992) presented the LCSFM images
of MITOX distribution within SV40 transformed human
fibroblasts. This study was based on the analysis of integral
fluorescence signal of the drug. Here we present the first
attempt to characterize the features of subcellular distribu-
tion of both MITOX and its complexes with cellular struc-
tures within intact, living K562 cells. For this purpose,
microfluorescence confocal spectral imaging analysis com-
bined with detailed in vitro modeling experiments was
performed.
Adequate in vitro modeling plays a key role in the inter-
pretation of the data, because the drug-associated intracel-
lular fluorescence may be affected by a number of multiple
factors, including ionic composition, pH, and polarity of the
environment, as well as specific and nonspecific molecular
interactions and metabolization of the drug within cellular
organelles. These factors often lead to prominent changes in
drug fluorescence, ranging from simple quenching or en-
hancement to remarkable shifts and changes in emission
spectrum. Therefore, the question of whether the fluores-
cence of the drug reflects its intracellular accumulation,
subcellular distribution, and interactions is important in
applications of flow cytometry, LCSFM, and CSI tech-
niques to analysis of the drug within living cells. Because so
far this question has not been elucidated for MITOX, we
performed a series of in vitro experiments to examine the
influence of different environmental factors and drug inter-
actions with potential intracellular targets on the fluores-
cence of MITOX.
The following effects and characteristics were observed:
1. dramatic quenching of drug fluorescence when the
drug was in the form of self-aggregates;
2. a characteristic spectral shift and enhancement of the
fluorescence of the drug when it was in a hydrophobic
environment;
3. a characteristic spectral shift and moderate quenching
of the fluorescence of the drug if it was complexed to
nucleic acids;
4. characteristic spectral features of the NQX metabolite
of MITOX.
FIGURE 6 Confocal spectral images of the cell measured (I) at the
equatorial optical cross section, and 3 ,um (II) and 6 ,im (III) above the
equatorial cross section. The cell was exposed to 10 ,uM MITOX concen-
tration for 1 h. (a-e) Spectral images describing the distribution of intrinsic
cellular fluorescence signal (a), nucleic acid-related complexes of MITOX
(b), monomeric MITOX in the aqueous intracellular environment (c), NQX
metabolite bound to the ligands (d), and MITOX bound to the hydrophobic
cellular structures (e). (f) Conventional light-microscope image of the cell.
The bar in f corresponds to 2 ,um.
All of these factors affecting the signal of MITOX should
be taken into account to reveal the real pattern of the drug
distribution and interactions within the cells.
Another important factor influencing measurements is
derived from intrinsic fluorescence properties of cells. The
results obtained for control and MITOX-treated K562 cells
show that 1) the spectrum of the intrinsic cellular fluores-
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cence is broad and overlaps the spectra of MITOX and its
complexes, 2) the relative contribution of the intrinsic cel-
lular fluorescence to overall drug-related signal is fairly
high, especially in the cells exposed to low concentrations
of the drug.
The analysis of MITOX accumulation and distribution in
the cells by flow cytometry and LSCFM techniques, based
on the measurements of integral signal selected with a
wide-band analyzing filter, could be considerably distorted
by a multicomponent character of the fluorescent signal. On
the other hand, the CSI technique makes it possible to easily
decompose overlapped spectra according to their origin.
Indeed, the time of spectral image accumulation (4 min in
the case of MITOX) is - 10-20-fold longer as compared to
LSCFM, based on the measurement of integral signal in-
tensity. In the case of the CSI technique, some part of the
signal is lost in the spectrometer (-40-50%), and addi-
tional time is needed to accumulate the spectrum. At the
same time, the resulting image obtained by the CSI tech-
nique has a much better signal-to-noise ratio as related to
the LSCFM image, because the signal is accumulated in the
100-200-nm spectral range (-10 nm in the case of LSCFM
image), and a very accurate correction for the background
fluorescence can be made. Because the same confocal sys-
tem of signal filtration is used, the spatial resolutions that
may be achieved are very similar for the two techniques.
Our results show that any fluorescence spectra recorded
from MITOX-treated cells could be reliably described as a
superposition of five characteristic signals, corresponding to
1) monomeric MITOX in an aqueous intracellular environ-
ment, 2) MITOX bound to hydrophobic cellular structures,
3) MITOX complexed with nucleic acids, 4) the NQX
metabolite, and 5) intrinsic cellular fluorescence. The de-
composition procedure being applied to the 2D set of spec-
tra allows the subcellular distribution of each component to
be mapped.
In addition, the 3D analysis was performed to clarify and
prove the features of the drug interactions. Generally, by
measuring confocal spectral images at different positions of
the focal plane along the z axis, a 3D model of intracellular
localization may be created for each component. At the
same time, it is necessary to ensure that the living cell and
distribution of the drug are not disrupted under irradiation.
Therefore, reconstruction of the complete 3D model is re-
stricted to the number of consequent measurements that
does not disturb the living cell and intracellular distribution
of the drug. In our experimental conditions, the 3D analysis
was restricted to five to seven measurements at the different
optical cross sections. For longer periods of irradiation, cells
were found to lyse. Although this number of measurements
was not enough to reconstruct a detailed 3D image, the main
features of localization and interactions of MITOX were
revealed. The 3D analysis confirms the data obtained when
the equatorial optical cross sections of cells were measured.
Therefore, all statistically important features of distribution
and interactions of the drug may be found by analyzing
comparatively different cells and averaging the data ob-
tained at the equatorial optical cross sections of a number of
the cells.
Three different states of MITOX can be traced in living
cells to micron resolution. Two of them, MITOX-nucleic
acid complexes and MITOX bound to hydrophobic cellular
structures, are suggested to be directly involved with the
antitumor action of the drug (Smith et al., 1990; Kapuscin-
ski and Darzynkiewicz, 1986; Roberts et al., 1989; Ho et al.,
1991). Furthermore, the NQX metabolite of MITOX was
detected in the K562 cells and its subcellular distribution
was established. The CSI technique has the advantage of
allowing this metabolite to be detected in the cells simulta-
neously with its parent compound, MITOX, and with com-
plexes formed by MITOX within the cellular structures and
molecules. Therefore, the dynamics and molecular mecha-
nism of MITOX metabolization can be studied. Moreover,
particular functions of metabolites (at least the NQX one),
MITOX bound to hydrophobic cellular structures and drug-
DNA complexes in the antitumor action of MITOX, can be
clarified with the help of CSI analysis. Quantitative analysis
of subcellular accumulation and distribution of MITOX and
drug-target complexes should precede the study of the
mechanisms, and it is the subject of our following paper.
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